On May 16, 2018, the Food and Drug Administration (FDA) approved Lucemyra (lofexidine hydrochloride) to lessen withdrawal symptoms related to abrupt discontinuation of opioids in adults. Lucemyra is the first non-opioid approved for use in a long term treatment plan for managing opioid use disorder (OUD).  The drug is only approved for treatment for up to 14 days. It is not approved as a stand-alone treatment for OUD. The FDA granted approval of Lucemyra to US WorldMeds, LLC. Read the FDA news release.